
Cirius Therapeutics Launches Phase 2 Trial for Type 1 Diabetes Drug
Cirius Therapeutics has initiated a Phase 2 clinical study of CIR-0602K, an experimental oral therapy aimed at addressing insulin resistance in adults with type 1 diabetes. Supported by a research award from Breakthrough T1D, the trial evaluates whether targeting mitochondrial dysfunction can improve glycemic control in patients using automated insulin delivery.

























